Emergent was “an obscure contractor in an obscure corner of the federal bureaucracy,” according to reporters at the New York Times who began looking into its operations as Covid unfolded, “applying ...

Emergent BioSolutions Inc. EBS stock rose Friday following the FDA approval of new multipack configurations of ...

This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million Program progress and performance ...

Quality control errors led millions of potential vaccines to be ruined. For Emergent BioSolutions, Feb. 8 was a day to revel in their success -- at least as far as the public was concerned. Standing ...

Emergent BioSolutions, Inc. (NYSE:EBS) shares surged higher Thursday after the company announced operational changes to stabilize its financial position and reported first-quarter financial results.

Emergent BioSolutions (NYSE:EBS) stock is trading higher on Thursday after the company announced the sale of its facility in Baltimore-Camden to Bora Pharmaceuticals. What Happened: On Thursday prior ...

An analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into ...

Emergent BioSolutions is showing signs of a potential turnaround with strategic restructuring, cost-cutting, and securing significant contracts in public health preparedness. Despite a challenging Q2, ...

With mpox cases still on the rise across Africa, Emergent BioSolutions' 2024 and 2025 orders for its arsenal of medical countermeasures have reached a total roughly $400 million, the company said.

Gaithersburg, Maryland-based Emergent BioSolutions has received Food and Drug Administration approval for use of its existing smallpox vaccine as a vaccine for the mpox virus. The vaccine, known as ...

Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness byincreasing flexibility and distribution efficiency of ...

Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence ...